ERBB2 and breast cancer: In MONALEESA 2-, 3-, and 7-trials, the largest biomarker analysis of any CDK4/6 inhibitor in advanced breast cancer [150], blood samples from 1507 ER+ HER2-metastatic breast cancer patients were analyzed at baseline using NGS with a targeted panel of 557 genes.